华润双鹤：羟钴胺注射液临床试验获批

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of Hydroxocobalamin injection, indicating progress in its drug development pipeline [1] Group 1: Regulatory Approval - The company announced on December 29 that it received the clinical trial approval notice for Hydroxocobalamin injection from the National Medical Products Administration [1] - The acceptance notice for the drug was received on October 22, 2025, and the clinical trial approval was granted on December 25, 2025 [1] Group 2: Financial Investment - As of the date of the announcement, the company has invested a total of RMB 13.0581 million (approximately 1.3 million) in the research and development of this drug [1] Group 3: Indication - Hydroxocobalamin injection is indicated for the treatment of metabolic disorders in children with methylmalonic acidemia, with or without homocystinuria [1]